Is Necitumumab available in China?

On November 24, 2015, the U.S. Food and Drug Administration (FDA) approved the EGFR antagonist Necitumumab intravenous injection (IV) in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer. Nexituzumab is not indicated for the treatment of patients with non-squamous non-small cell lung cancer. EGFR protein is expressed in most non-small cell lung cancer tumors, especially in squamous cell diseases. The recombinant human immunoglobulin (Ig) G1 monoclonal antibody oxetuzumab is an EGFR antagonist with potential anti-tumor activity. The low-sodium oxetuzumab generic drug has not been approved for marketing in China and has not been included in medical insurance.